BridgeMD
New treatment option for Intracerebral Hemorrhage
Official title Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage
ClinicalTrials.gov ID: NCT05434065
What this study is testing
What is Celecoxib 200mg?
Celecoxib 200mg is an investigational medicine, being studied as a potential treatment for intracerebral hemorrhage.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This trial is a phase IIa human clinical study, in which 60 patients with intracerebral hemorrhage (ICH) at basal ganglion or thalamus within 6 h after onset will be enrolled. Patients will be randomly assigned as treatment group or control group as 1:1 distribution.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 80
You may be able to join if
- Acute ICH patients able to take the first dose within 6 hours after onset
- ICH location at basal ganglion or thalamus
- ICH volume \< 30 mL
- Normal renal function (creatinine [Cr] ≤ 1.3 mg/dL)
- No surgical indication
You likely can't join if
- Allergy to celecoxib or other non-steroid anti-inflammatory drugs (NSAIDs)
- Post-coronary artery bypass graft (CABG) within 14 days
- Previous myocardial infarction
- Previous peptic ulcer disease
- Abnormal renal function (Cr \> 1.3 mg/dL)
- Surgery for this ICH
See the full eligibility criteria
- Acute ICH patients able to take the first dose within 6 hours after onset
- ICH location at basal ganglion or thalamus
- ICH volume \< 30 mL
- Normal renal function (creatinine [Cr] ≤ 1.3 mg/dL)
- No surgical indication
- Signed informed consent
- Consciousness clear or mild drowsiness
- Age 20-80 years old
- Allergy to celecoxib or other non-steroid anti-inflammatory drugs (NSAIDs)
- Post-coronary artery bypass graft (CABG) within 14 days
- Previous myocardial infarction
- Previous peptic ulcer disease
- Abnormal renal function (Cr \> 1.3 mg/dL)
- Surgery for this ICH
- Pregnancy or under breast feeding (If the female case is not sure about pregnancy, pregnancy test will be performed)
- Premorbid mRS \> or = 3
- Previous ICH not at basal ganglia or thalamus
- Coagulation abnormality (abnormal PT/PTT), or taking anticoagulant or antiplatelet
- Abnormal liver function (ALT \> 3x upper limit)
- History of severe bleeding event, requiring admission or blood transfusion
- History of stenting or valve replacement, requiring long-term using antithrombotics
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Taiwan
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.